Surveillance for Guillain-Barré syndrome after influenza vaccination among U.S. Medicare beneficiaries during the 2017-2018 season
- PMID: 31122853
- DOI: 10.1016/j.vaccine.2019.05.041
Surveillance for Guillain-Barré syndrome after influenza vaccination among U.S. Medicare beneficiaries during the 2017-2018 season
Abstract
Background: The U.S. Food and Drug Administration and the Centers for Medicare & Medicaid Services have been actively monitoring the risk of Guillain-Barré syndrome (GBS) following influenza vaccination among Fee-for-Service (FFS) Medicare beneficiaries every season since 2008. We present our evaluation of the GBS risk following influenza vaccinations during the 2017-2018 season.
Methods: We implemented a multilayered approach to active safety surveillance that included near real-time surveillance early in the season, comparing GBS rates post-vaccination during the 2017-2018 season with rates from five prior seasons using the Updating Sequential Probability Ratio Test (USPRT), and end-of-season self-controlled risk interval (SCRI) analyses.
Results: We identified approximately 16 million influenza vaccinations. The near real-time surveillance did not signal for a potential 2.5-fold increased GBS risk either in days 8-21 or 1-42 post-influenza vaccination. In the SCRI analyses, we did not detect statistically significant increased GBS risks among influenza-vaccinated Medicare beneficiaries ≥65 years for either the 8-21 or 1-42-day risk windows for all seasonal vaccines combined, high-dose vaccine, or standard-dose vaccines; we did detect an increased GBS risk in days 8-21 post-vaccination for individuals vaccinated with the adjuvanted vaccine (OR: 3.75; 95% CI: 1.01, 13.96), although this finding was not statistically significant after multiplicity adjustment (p = 0.146).
Conclusions: Our multilayered surveillance approach-which allows for early detection of elevated GBS risk and provides reliable end-of-season SCRI estimates of effect size-did not identify an increased GBS risk following 2017-2018 influenza vaccinations. The slightly increased GBS risk with the adjuvanted vaccine, which was not statistically significant following multiplicity adjustment, is consistent with the package inserts of all U.S.-licensed influenza vaccines, which warn of a potential low increased GBS risk. The benefits of influenza vaccines in preventing morbidity and mortality heavily outweigh this potential risk.
Keywords: Guillain-Barré syndrome; Influenza vaccines; Near real-time surveillance; Self-controlled risk interval; Sequential tests; Vaccine safety.
Published by Elsevier Ltd.
Similar articles
-
Surveillance for Guillain-Barré syndrome after 2015-2016 and 2016-2017 influenza vaccination of Medicare beneficiaries.Vaccine. 2019 Oct 8;37(43):6543-6549. doi: 10.1016/j.vaccine.2019.08.045. Epub 2019 Sep 9. Vaccine. 2019. PMID: 31515146
-
Near real-time surveillance for Guillain-Barré syndrome after influenza vaccination among the Medicare population, 2010/11 to 2013/14.Vaccine. 2017 May 19;35(22):2986-2992. doi: 10.1016/j.vaccine.2017.03.087. Epub 2017 Apr 24. Vaccine. 2017. PMID: 28449973
-
Chart-confirmed guillain-barre syndrome after 2009 H1N1 influenza vaccination among the Medicare population, 2009-2010.Am J Epidemiol. 2013 Sep 15;178(6):962-73. doi: 10.1093/aje/kwt051. Epub 2013 May 6. Am J Epidemiol. 2013. PMID: 23652165
-
Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence.Clin Infect Dis. 2014 Apr;58(8):1149-55. doi: 10.1093/cid/ciu005. Epub 2014 Jan 9. Clin Infect Dis. 2014. PMID: 24415636 Review.
-
Guillain-Barré syndrome and influenza vaccines: A meta-analysis.Vaccine. 2015 Jul 17;33(31):3773-8. doi: 10.1016/j.vaccine.2015.05.013. Epub 2015 May 18. Vaccine. 2015. PMID: 25999283 Review.
Cited by
-
Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older.Vaccine. 2023 Jan 9;41(2):532-539. doi: 10.1016/j.vaccine.2022.11.069. Epub 2022 Dec 1. Vaccine. 2023. PMID: 36496287 Free PMC article.
-
Environmental factors influencing the risk of ANCA-associated vasculitis.Front Immunol. 2022 Sep 2;13:991256. doi: 10.3389/fimmu.2022.991256. eCollection 2022. Front Immunol. 2022. PMID: 36119110 Free PMC article. Review.
-
Guillain-Barré Syndrome Following Influenza Vaccines Affords Opportunity to Improve Vaccine Confidence.J Infect Dis. 2021 Feb 13;223(3):355-358. doi: 10.1093/infdis/jiaa544. J Infect Dis. 2021. PMID: 33137189 Free PMC article. No abstract available.
-
Guillain-Barré Syndrome After High-Dose Influenza Vaccine Administration in the United States, 2018-2019 Season.J Infect Dis. 2021 Feb 13;223(3):416-425. doi: 10.1093/infdis/jiaa543. J Infect Dis. 2021. PMID: 33137184 Free PMC article.
-
Antigenic Variability a Potential Factor in Assessing Relationship Between Guillain Barré Syndrome and Influenza Vaccine - Up to Date Literature Review.Cureus. 2020 Sep 2;12(9):e10208. doi: 10.7759/cureus.10208. Cureus. 2020. PMID: 33033684 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical